Cargando…
Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases
In recent years, local governments in Japan have established a public financial support system for fertility preservation in pediatric, adolescent, and young adult cancer patients. Fertility preservation has become popular for patients with cancers included in the gonadal toxicity risk classificatio...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850228/ https://www.ncbi.nlm.nih.gov/pubmed/34791542 http://dx.doi.org/10.1007/s10147-021-02082-9 |
_version_ | 1784652548112646144 |
---|---|
author | Ono, Masanori Matsumoto, Kimikazu Boku, Narikazu Fujii, Nobuharu Tsuchida, Yumi Furui, Tatsuro Harada, Miyuki Kanda, Yoshinobu Kawai, Akira Miyachi, Mitsuru Murashima, Atsuko Nakayama, Robert Nishiyama, Hiroyuki Shimizu, Chikako Sugiyama, Kazuhiko Takai, Yasushi Fujio, Keishi Morishige, Ken-Ichirou Osuga, Yutaka Suzuki, Nao |
author_facet | Ono, Masanori Matsumoto, Kimikazu Boku, Narikazu Fujii, Nobuharu Tsuchida, Yumi Furui, Tatsuro Harada, Miyuki Kanda, Yoshinobu Kawai, Akira Miyachi, Mitsuru Murashima, Atsuko Nakayama, Robert Nishiyama, Hiroyuki Shimizu, Chikako Sugiyama, Kazuhiko Takai, Yasushi Fujio, Keishi Morishige, Ken-Ichirou Osuga, Yutaka Suzuki, Nao |
author_sort | Ono, Masanori |
collection | PubMed |
description | In recent years, local governments in Japan have established a public financial support system for fertility preservation in pediatric, adolescent, and young adult cancer patients. Fertility preservation has become popular for patients with cancers included in the gonadal toxicity risk classification of the 2017 edition of the Guideline for Fertility Preservation in Children, Adolescents and Young Adult Cancer Patients from the Japan Society of Clinical Oncology. However, patients with cancer and non-cancer diseases that are not included in the Guideline’s gonadal toxicity risk classification also often receive treatment that may affect fertility, but they are often denied the opportunity of fertility preservation because no public financial support is available for diseases not listed in the Guideline. The national research project proposes including these diseases in the indications and treatment for fertility preservation. Therefore, we cooperated with the Japan Society for Fertility Preservation and the Ministry of Health, Labour and Welfare research group to solicit opinions from experts in each therapeutic area and reviewed the literature and overseas guidelines. This paper summarizes the findings of the project. We believe that it will be an important source of information for clinicians treating patients who need fertility preservation but note that the appropriateness of fertility preservation for the disorders listed in this report needs to be continuously reviewed as medical care advances. |
format | Online Article Text |
id | pubmed-8850228 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-88502282022-02-23 Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases Ono, Masanori Matsumoto, Kimikazu Boku, Narikazu Fujii, Nobuharu Tsuchida, Yumi Furui, Tatsuro Harada, Miyuki Kanda, Yoshinobu Kawai, Akira Miyachi, Mitsuru Murashima, Atsuko Nakayama, Robert Nishiyama, Hiroyuki Shimizu, Chikako Sugiyama, Kazuhiko Takai, Yasushi Fujio, Keishi Morishige, Ken-Ichirou Osuga, Yutaka Suzuki, Nao Int J Clin Oncol Invited Review Article In recent years, local governments in Japan have established a public financial support system for fertility preservation in pediatric, adolescent, and young adult cancer patients. Fertility preservation has become popular for patients with cancers included in the gonadal toxicity risk classification of the 2017 edition of the Guideline for Fertility Preservation in Children, Adolescents and Young Adult Cancer Patients from the Japan Society of Clinical Oncology. However, patients with cancer and non-cancer diseases that are not included in the Guideline’s gonadal toxicity risk classification also often receive treatment that may affect fertility, but they are often denied the opportunity of fertility preservation because no public financial support is available for diseases not listed in the Guideline. The national research project proposes including these diseases in the indications and treatment for fertility preservation. Therefore, we cooperated with the Japan Society for Fertility Preservation and the Ministry of Health, Labour and Welfare research group to solicit opinions from experts in each therapeutic area and reviewed the literature and overseas guidelines. This paper summarizes the findings of the project. We believe that it will be an important source of information for clinicians treating patients who need fertility preservation but note that the appropriateness of fertility preservation for the disorders listed in this report needs to be continuously reviewed as medical care advances. Springer Singapore 2021-11-17 2022 /pmc/articles/PMC8850228/ /pubmed/34791542 http://dx.doi.org/10.1007/s10147-021-02082-9 Text en © The Author(s) 2021, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Invited Review Article Ono, Masanori Matsumoto, Kimikazu Boku, Narikazu Fujii, Nobuharu Tsuchida, Yumi Furui, Tatsuro Harada, Miyuki Kanda, Yoshinobu Kawai, Akira Miyachi, Mitsuru Murashima, Atsuko Nakayama, Robert Nishiyama, Hiroyuki Shimizu, Chikako Sugiyama, Kazuhiko Takai, Yasushi Fujio, Keishi Morishige, Ken-Ichirou Osuga, Yutaka Suzuki, Nao Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases |
title | Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases |
title_full | Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases |
title_fullStr | Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases |
title_full_unstemmed | Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases |
title_short | Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases |
title_sort | indications for fertility preservation not included in the 2017 japan society of clinical oncology guideline for fertility preservation in pediatric, adolescent, and young adult patients treated with gonadal toxicity, including benign diseases |
topic | Invited Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850228/ https://www.ncbi.nlm.nih.gov/pubmed/34791542 http://dx.doi.org/10.1007/s10147-021-02082-9 |
work_keys_str_mv | AT onomasanori indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT matsumotokimikazu indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT bokunarikazu indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT fujiinobuharu indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT tsuchidayumi indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT furuitatsuro indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT haradamiyuki indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT kandayoshinobu indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT kawaiakira indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT miyachimitsuru indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT murashimaatsuko indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT nakayamarobert indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT nishiyamahiroyuki indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT shimizuchikako indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT sugiyamakazuhiko indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT takaiyasushi indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT fujiokeishi indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT morishigekenichirou indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT osugayutaka indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases AT suzukinao indicationsforfertilitypreservationnotincludedinthe2017japansocietyofclinicaloncologyguidelineforfertilitypreservationinpediatricadolescentandyoungadultpatientstreatedwithgonadaltoxicityincludingbenigndiseases |